Imagine your vision slowly blurring and your eye swelling after cataract surgery. That's the reality of Irvine-Gass syndrome (IGS), a frustrating complication that can steal a person's clear sight. A new review of past patient records looked at whether injections of a drug called anti-VEGF directly into the eye could help. The review pooled data from 334 patients (343 eyes) who received these injections. After about six months, on average, patients' vision improved and the swelling in the center of their eye decreased. In the few studies that tracked it, the fluid buildup causing the problem resolved in a majority of eyes. This is encouraging news for a condition with limited treatment options. However, it's important to understand what this review can and cannot tell us. The main finding comes with significant caution. The studies were mostly retrospective, meaning researchers looked back at old medical charts rather than designing a controlled experiment. The way different studies reported their main results was too messy to combine for a stronger analysis. Most importantly, we still don't know if these injections work better than a simple placebo injection, because only one small study made that direct comparison. The review suggests potential benefit, but it's a signal calling for better, more definitive research.
Intravitreal Anti-VEGF Shows Anatomic and Visual Gains in Irvine-Gass Syndrome Meta-AnalysisCan eye injections help people with Irvine-Gass syndrome see better?
AI-generated summary of the cited source, checked by automated accuracy review. How we work
Key Takeaway
Consider anti-VEGF for IGS based on retrospective data showing visual/anatomic gains, but superiority over placebo is uncertain.
This systematic review and meta-analysis evaluated the efficacy of intravitreal anti-VEGF agents for Irvine-Gass syndrome (IGS), pooling data from 343 eyes of 334 patients. The analysis included seven retrospective studies and one randomized, sham-controlled, multicenter study, with a mean follow-up of 6.0 months. The comparator was sham injection in the single randomized trial; other studies lacked a formal control group.
At 6 months, treatment was associated with a mean improvement in best-corrected visual acuity (BCVA) of 0.65 logMAR (95% CI: -0.83; -0.47) and a mean decrease in central macular thickness (CMT) of 290.41 µm (95% CI: -351.33; -229.54). In the three studies reporting it, the percentage of eyes achieving resolution of cystoid macular edema (CME) ranged from 66.4% to 100%. Safety and tolerability data were not reported.
Key limitations significantly constrain the findings. The primary outcome of CME resolution was reported too heterogeneously to allow for meta-analysis. Superiority over placebo remains uncertain, as most evidence comes from retrospective studies. The authors note a need for randomized, placebo-controlled trials.
For practice, this analysis suggests potential anatomic and functional benefits of intravitreal anti-VEGF in treating IGS, but the evidence is not definitive. Clinicians should interpret these associations cautiously due to the study designs and lack of comparative efficacy data against other treatments or placebo.
What this means for you:
Eye injections show promise for Irvine-Gass syndrome, but stronger studies are needed to prove they work best. More on Cystoid Macular Edema
Meta-analysis: Anti-VEGF biosimilars show equivalent efficacy, safety to reference agents in nAMD
Can cheaper eye drugs work as well as expensive ones? A major review says yes for vision loss in older adults
A meta-analysis of 17 RCTs (n=6694) found no clinically meaningful differences in BCVA improvement at 12 weeks (MD=-0.42, p=0.17) or endpoin…
Cheaper eye drug copies work just as well as expensive originals for treating vision loss in older adults, a major review confirms.
Budget impact analysis of switching to ranibizumab biosimilar for retinal diseases in Jordan
Jordan Eye Drug Biosimilar Slashes Costs and Boosts Patient Access
This budget impact analysis from a Jordanian public sector perspective estimates that switching from aflibercept to ranibizumab's biosimilar…
Switching to a biosimilar version of a common eye drug could save Jordan’s public health system millions and help more patients get treatmen…
Angiogenesis inhibitors combined with chemotherapy improve progression-free survival in advanced breast cancer patients
Adding angiogenesis inhibitors to chemotherapy helps advanced breast cancer patients stay disease-free longer
This systematic review and meta-analysis of phase II and III trials evaluated angiogenesis inhibitors combined with chemotherapy versus chem…
A large review of eight thousand four hundred patients found that adding angiogenesis inhibitors to standard chemotherapy improved how long …
Lenvatinib plus PD-1 inhibitor improves survival versus bevacizumab plus PD-1 inhibitor in unresectable hepatocellular carcinoma
Meta-analysis shows lenvatinib-based regimens improve survival for unresectable liver cancer in East Asia
This systematic review and meta-analysis evaluated first-line treatment for unresectable hepatocellular carcinoma in East Asian populations.
A meta-analysis of East Asian patients with unresectable liver cancer found lenvatinib-based regimens improved survival compared to bevacizu…
View Original Abstract ↓
PURPOSE: To investigate the efficacy of intravitreal anti-VEGF agents in the treatment of Irvine-Gass syndrome (IGS).
METHODS: Systematic review with meta-analysis. The primary outcome was the percentage with resolution of cystoid macular edema (CME). Secondary outcomes were changes in best-corrected visual acuity (BCVA) and central macular thickness (CMT) from baseline to time of follow-up. A meta-analysis was conducted on changes in BCVA and CMT from baseline to a 6-month follow-up visit.
RESULTS: Seven retrospective studies and one randomized, sham-controlled, multicenter study provided data on a total of 343 eyes of 334 patients. The primary outcome was reported too heterogeneously to allow for meta-analysis, but three studies reported resolution of CME during follow-up in 66.4% to 100% of eyes treated. At 6 months after treatment initiation, the mean improvement in BCVA was 0.65 (95%CI: -0.83; -0.47) logMAR, and the mean decrease in CMT was 290.41 (95%CI: -351.33; -229.54) µm.
CONCLUSION: Current literature suggests potential benefits of intravitreal anti-VEGF in treating IGS. However, its superiority over placebo remains uncertain, suggesting the need for randomized, placebo-controlled trials.
Systematic review of extensive macular atrophy with pseudodrusen reports visual acuity decline and atrophy progression
Eye disease linked to vision loss and thicker eye layers in study
Related in Ophthalmology
FDA Approves Fluorescite (fluorescein sodium) for Retinal and Iris Angiography
FDA approves Fluorescite injection for eye imaging tests.
The FDA approved Fluorescite Injection 10% for diagnostic fluorescein angiography or angioscopy of the retina and iris vasculature. The adul…
The FDA approved Fluorescite Injection 10% for use in eye imaging tests to examine blood flow in the retina and iris. It helps doctors detec…
Combined phacoemulsification and angle filtering reduce intraocular pressure and medication needs in glaucoma patients
Combined surgery lowers eye pressure better than cataract surgery alone
This meta-analysis of 14 randomized controlled trials evaluated combined phacoemulsification and angle filtering compared to phacoemulsifica…
For glaucoma patients with cataracts, combining two procedures in one surgery may better protect vision than cataract surgery alone.
Intravitreal ziv-aflibercept reduces central macular thickness and improves visual acuity in DME and RVO
Trial shows ziv-aflibercept improves vision in macular edema cases
This systematic review and meta-analysis of 5 RCTs and 8 observational studies found that intravitreal ziv-aflibercept significantly reduced…
A new eye treatment called ziv-aflibercept may help reduce swelling and improve vision for patients with specific types of macular edema.
Glaucoma drainage device implantation yields 65% success rate in uveitic glaucoma meta-analysis
Glaucoma Drainage Devices Show Promise for Uveitic Glaucoma
This systematic review and meta-analysis of 38 studies (1083 eyes) found an overall surgical success rate of 65.40% for glaucoma drainage de…
A review of 38 studies finds drainage devices help lower eye pressure in uveitic glaucoma, with different devices offering distinct benefits…
From Other Specialties
Prenatal 6:2 Cl-PFESA exposure is associated with lower birth weight in infants across specific sub-analyses
Chemical in everyday products linked to lower birth weight
This meta-analysis of 12 studies examined the association between prenatal 6:2 Cl-PFESA exposure and infant birth weight. While no overall s…
A common chemical may reduce newborn weight by up to 20 grams. New analysis of 12 studies raises concerns for fetal health.
Reducing social media use to 1 hour daily significantly reduces loneliness in youth
Limiting Social Media Use Reduces Loneliness in Youth with Anxiety
This randomized controlled trial of 219 youth with anxiety or depression found that limiting social media use to 1 hour per day for three we…
Youth with anxiety and depression felt less lonely after voluntarily limiting their social media use to one hour per day for three weeks.
GLP-1R exposure shows no causal link to most mental disorders except eating disorders
GLP-1 Receptor Agonists Show Mixed Links to Mental Health
This meta-analysis investigated the causal associations between GLP-1 receptor agonists and various mental health outcomes including anxiety…
New research explores how GLP-1 receptor agonists relate to conditions like anxiety and depression, finding no clear genetic link to most di…
Sacubitril/Valsartan preserves left ventricular systolic function and attenuates GLS deterioration during chemotherapy
Sacubitril and Valsartan May Protect Heart Function During Chemotherapy
This meta-analysis of randomized controlled trials evaluates sacubitril/valsartan for patients undergoing chemotherapy to manage chemotherap…
A new review suggests the medication sacubitril/valsartan may help preserve heart muscle function for patients undergoing chemotherapy.